{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:34:06Z","timestamp":1774121646463,"version":"3.50.1"},"reference-count":35,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1513,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1111\/j.1365-2710.2011.01285.x","type":"journal-article","created":{"date-parts":[[2011,7,11]],"date-time":"2011-07-11T07:38:48Z","timestamp":1310369928000},"page":"204-211","source":"Crossref","is-referenced-by-count":31,"title":["Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis"],"prefix":"10.1155","volume":"37","author":[{"given":"J.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2011,7,11]]},"reference":[{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/thorax.57.10.847","article-title":"Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease","volume":"57","author":"Donaldson","year":"2002","journal-title":"Thorax"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/thx.2005.040527","article-title":"Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease","volume":"60","author":"Soler-Cataluna","year":"2005","journal-title":"Thorax"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB3|cit3","unstructured":"Global initiative for chronic obstructive lung disease (GOLD): report of the GOLD workshop, global strategy for diagnosis, management and prevention of COPD http:\/\/www.goldcopd.com"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","article-title":"Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD","volume":"65","author":"Dahl","year":"2010","journal-title":"Thorax"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","article-title":"Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium","volume":"182","author":"Donohue","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1378\/chest.07-1167","article-title":"Safety of long-acting \u03b2-agonists in stable COPD","volume":"133","author":"Rodrigo","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1592\/phco.29.8.891","article-title":"Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed treatment comparison meta-analysis","volume":"29","author":"Baker","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1741-7015-7-2","article-title":"Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis","volume":"7","author":"Puhan","year":"2009","journal-title":"BMC Medicine"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.rmed.2003.09.001","article-title":"COPD exacerbations: the importance of a standard definition","volume":"98","author":"Pauwels","year":"2004","journal-title":"Respiratory Medicine"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00161507","article-title":"Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited","volume":"32","author":"Keene","year":"2008","journal-title":"European Respiratory Journal"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1183\/09031936.00124108","article-title":"Statistical analysis of COPD exacerbations (letter)","volume":"32","author":"Liu","year":"2008","journal-title":"European Respiratory Journal"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"398S","DOI":"10.1378\/chest.117.5_suppl_2.398S","article-title":"Toward a consensus definition for COPD exacerbations","volume":"117","author":"Rodriguez-Roisin","year":"2000","journal-title":"Chest"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"European Respiratory Journal"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"European Respiratory Journal"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1094-5539(03)00065-8","article-title":"Salmeterol and fluticasone 50 microg\/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline","volume":"16","author":"Dal Negro","year":"2003","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/thorax.58.5.399","article-title":"Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD","volume":"58","author":"Brusasco","year":"2003","journal-title":"Thorax"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial","volume":"361","author":"Calverley","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1155\/2002\/493296","article-title":"The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease","volume":"9","author":"Chapman","year":"2002","journal-title":"Canadian Respiratory Journal"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250 microg)\/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD","volume":"124","author":"Hanania","year":"2003","journal-title":"Chest"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"Mahler","year":"2002","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/thx.2004.033266","article-title":"Addition of salmeterol to existing treatment in patients with COPD: a 12\u2003month study","volume":"61","author":"Stockley","year":"2006","journal-title":"Thorax"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1183\/09031936.03.00027003","article-title":"Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease","volume":"22","author":"Calverley","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.rmed.2005.08.016","article-title":"Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease","volume":"99","author":"Campbell","year":"2005","journal-title":"Respiratory Medicine"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2165\/00003495-200969050-00004","article-title":"Efficacy and tolerability of budesonide\/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial","volume":"69","author":"Rennard","year":"2009","journal-title":"Drugs"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1378\/chest.121.4.1058","article-title":"Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD","volume":"121","author":"Rossi","year":"2002","journal-title":"Chest"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1183\/09031936.03.00031402","article-title":"Efficacy and safety of budesonide\/formoterol in the management of chronic obstructive pulmonary disease","volume":"21","author":"Szafranski","year":"2003","journal-title":"European Respiratory Journal"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2165\/00003495-200868140-00004","article-title":"Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial","volume":"68","author":"Tashkin","year":"2008","journal-title":"Drugs"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.rmed.2008.07.020","article-title":"Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study","volume":"102","author":"Vogelmeier","year":"2008","journal-title":"Respiratory Medicine"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1056\/NEJMoa032158","article-title":"The nature of small airway obstruction in chronic obstructive pulmonary disease","volume":"350","author":"Hogg","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2710.2011.01285.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1378\/chest.118.6.1557","article-title":"Airway inflammation and etiology of acute exacerbations of chronic bronchitis","volume":"18","author":"Sethi","year":"2000","journal-title":"Chest"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2011.01285.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2011.01285.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:12Z","timestamp":1671818652000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2011.01285.x"}},"subtitle":["LABAs in COPD exacerbations"],"short-title":[],"issued":{"date-parts":[[2011,7,11]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2011.01285.x","relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,11]]}}}